[1] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[2] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[3] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[4] |
CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming.
Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
|
[5] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[6] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[7] |
ZANG Tianying, LIU Bingyang, TANG Xiaojun.
Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
|
[8] |
CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan.
One case of abnormal uterine bleeding caused by Baofukang suppository
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
|
[9] |
WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun.
Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
|
[10] |
ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia.
Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
|
[11] |
LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun.
Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
|
[12] |
CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao.
Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
|
[13] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[14] |
CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin.
Analysis of reports of allergic shock in Chongqing between 2015 and 2020
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
|
[15] |
OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying.
One case of breast hyperplasia caused by digoxin tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.
|